+

WO1999009967A3 - Cholesterol-lowering therapy - Google Patents

Cholesterol-lowering therapy Download PDF

Info

Publication number
WO1999009967A3
WO1999009967A3 PCT/US1998/017459 US9817459W WO9909967A3 WO 1999009967 A3 WO1999009967 A3 WO 1999009967A3 US 9817459 W US9817459 W US 9817459W WO 9909967 A3 WO9909967 A3 WO 9909967A3
Authority
WO
WIPO (PCT)
Prior art keywords
cholesterol level
average
density lipoprotein
cholesterol
lipoprotein cholesterol
Prior art date
Application number
PCT/US1998/017459
Other languages
French (fr)
Other versions
WO1999009967B1 (en
WO1999009967A2 (en
Inventor
Edwin J Whitney
Geraldine Mantell
Original Assignee
Merck & Co Inc
Edwin J Whitney
Geraldine Mantell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9814415.7A external-priority patent/GB9814415D0/en
Priority claimed from GBGB9815851.2A external-priority patent/GB9815851D0/en
Application filed by Merck & Co Inc, Edwin J Whitney, Geraldine Mantell filed Critical Merck & Co Inc
Priority to CA002300165A priority Critical patent/CA2300165A1/en
Priority to EP98943329A priority patent/EP1007019A2/en
Priority to AU91153/98A priority patent/AU9115398A/en
Publication of WO1999009967A2 publication Critical patent/WO1999009967A2/en
Publication of WO1999009967A3 publication Critical patent/WO1999009967A3/en
Publication of WO1999009967B1 publication Critical patent/WO1999009967B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Methods are described for preventing or reducing the risk of a first occurrence of a cardiovascular event using an HMG-CoA reductase inhibitor alone or in combination with another lipid altering agent. Subjects to be treated are those having an average serum total cholesterol level, an average to mildly elevated serum low-density lipoprotein cholesterol level, and a below average serum high-density lipoprotein cholesterol level, with no history of clinically evident coronary disease.
PCT/US1998/017459 1997-08-26 1998-08-21 Cholesterol-lowering therapy WO1999009967A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002300165A CA2300165A1 (en) 1997-08-26 1998-08-21 Cholesterol-lowering therapy
EP98943329A EP1007019A2 (en) 1997-08-26 1998-08-21 Cholesterol-lowering therapy
AU91153/98A AU9115398A (en) 1997-08-26 1998-08-21 Cholesterol-lowering therapy

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US5696697P 1997-08-26 1997-08-26
US60/056,966 1997-08-26
US7685998P 1998-03-05 1998-03-05
US60/076,859 1998-03-05
US8536098P 1998-05-13 1998-05-13
US60/085,360 1998-05-13
GB9814415.7 1998-07-03
GBGB9814415.7A GB9814415D0 (en) 1998-07-03 1998-07-03 Cholesterol-lowering therapy
GB9815851.2 1998-07-21
GBGB9815851.2A GB9815851D0 (en) 1998-07-21 1998-07-21 Cholesterol-lowering therapy

Publications (3)

Publication Number Publication Date
WO1999009967A2 WO1999009967A2 (en) 1999-03-04
WO1999009967A3 true WO1999009967A3 (en) 1999-05-20
WO1999009967B1 WO1999009967B1 (en) 1999-07-08

Family

ID=27517467

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1998/017459 WO1999009967A2 (en) 1997-08-26 1998-08-21 Cholesterol-lowering therapy

Country Status (4)

Country Link
EP (1) EP1007019A2 (en)
AU (1) AU9115398A (en)
CA (1) CA2300165A1 (en)
WO (1) WO1999009967A2 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246894T3 (en) 1999-08-30 2006-03-01 Sanofi-Aventis Deutschland Gmbh RAMIPRIL FOR THE PREVENTION OF CARDIOVASCULAR EVENTS.
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
IL156422A0 (en) 2001-01-26 2004-01-04 Schering Corp The use of substituted azetidinone compounds for the treatment of sitosterolemia
CA2563051A1 (en) 2001-01-26 2002-08-01 Schering Corporation Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications
ATE345793T1 (en) 2001-09-21 2006-12-15 Schering Corp TREATMENT OF XANTHOMA USING AZETIDINONE DERIVATIVES AS STEROL ABSORPTION INHIBITORS
US7056906B2 (en) 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2004043456A1 (en) 2002-11-06 2004-05-27 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
JP2006519869A (en) 2003-03-07 2006-08-31 シェーリング　コーポレイション Substituted azetidinone compounds, processes for preparing substituted azetidinone compounds, their formulations and uses
ES2318274T3 (en) 2003-03-07 2009-05-01 Schering Corporation AZETIDINONA SUBSTITUTED COMPOUNDS, FORMULATIONS AND USE OF THE SAME FOR THE TREATMENT OF HYPERCHOLESTEROLEMIA.
ATE406364T1 (en) 2003-03-07 2008-09-15 Schering Corp SUBSTITUTED AZETIDINONE DERIVATIVES, THEIR PHARMACEUTICAL FORMULATIONS AND THEIR USE IN THE TREATMENT OF HYPERCHOLESTEROLEMIA

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0461548A2 (en) * 1990-06-11 1991-12-18 E.R. SQUIBB & SONS, INC. Method for preventing a second heart attack employing and HMG CoA reductase inhibitor
EP0528515A2 (en) * 1991-06-04 1993-02-24 Merck & Co. Inc. HMG-CoA reductase inhibitors in the prevention of restenosis following coronary angioplasty
EP0671171A1 (en) * 1994-01-18 1995-09-13 Bristol-Myers Squibb Company Use of HMG COA reductase inhibitor for the manufacture of a medicament for proventing or reducing risks of onset of cardiovascular events
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0461548A2 (en) * 1990-06-11 1991-12-18 E.R. SQUIBB & SONS, INC. Method for preventing a second heart attack employing and HMG CoA reductase inhibitor
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
EP0528515A2 (en) * 1991-06-04 1993-02-24 Merck & Co. Inc. HMG-CoA reductase inhibitors in the prevention of restenosis following coronary angioplasty
EP0671171A1 (en) * 1994-01-18 1995-09-13 Bristol-Myers Squibb Company Use of HMG COA reductase inhibitor for the manufacture of a medicament for proventing or reducing risks of onset of cardiovascular events

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
HARIA M. ET AL: "Pravastatin: A reappraisal of its pharmacological properties and clinical effectiveness in the management of coronary heart disease.", DRUGS, (1997) 53/2 (299-336). REFS: 267 ISSN: 0012-6667 CODEN: DRUGAY, New Zealand, XP002095845 *
KELLICK K A ET AL: "Outcome monitoring of fluvastatin in a Department of Veterans Affairs lipid clinic.", AMERICAN JOURNAL OF CARDIOLOGY, (1995 JUL 13) 76 (2) 62A-64A. JOURNAL CODE: 3DQ. ISSN: 0002-9149., United States, XP002095843 *
MARCUS A.: "Role of the HMG-CoA reductase inhibitors in the treatment of dyslipidemia An evolutionary review.", CARDIOVASCULAR REVIEWS AND REPORTS, (1996) 17/1 (10-11+15-16+21-24+26-27) ISSN: 0197-3118 CODEN: CRRPD4, United States, XP002095841 *
MEISER, B. M. ET AL: "Simvastatin decreases accelerated graft vessel disease (GVD) after heart transplantation in an animal model", TRANSPLANT. PROC. (1993), 25(2), 2077-9 CODEN: TRPPA8;ISSN: 0041-1345, XP002095842 *
MOTOMURA N. ET AL: "HMG-CoA reductase inhibitors in organ transplantation.", JOURNAL OF NEPHROLOGY, (1997) 10/2 (68-76). REFS: 127 ISSN: 1121-8428 CODEN: JLNEEL, Italy, XP002095844 *
PFEIFER M.A. ET AL: "Cholesterol and recurrent events: A secondary prevention trial for normolipidemic patients.", AMERICAN JOURNAL OF CARDIOLOGY, (1995) 76/9 (98C-106C). ISSN: 0002-9149 CODEN: AJCDAG, United States, XP000579209 *
PROBSTFIELD, JEFFREY L. (1) ET AL: "Results of the primary outcome measure and clinical events from the asymptomatic carotid artery progression study.", AMERICAN JOURNAL OF CARDIOLOGY, (1995) VOL. 76, NO. 9, PP. 47C-53C. ISSN: 0002-9149., XP002095840 *
SOUTHWORTH M R ET AL: "The use of HMG-CoA reductase inhibitors to prevent accelerated graft atherosclerosis in heart transplant patients.", ANNALS OF PHARMACOTHERAPY, (1997 APR) 31 (4) 489-91. REF: 32 JOURNAL CODE: BBX. ISSN: 1060-0280., United States, XP002095847 *
STEIN E. ET AL: "Cerivastatin, a new potent synthetic HMG Co-A reductase inhibitor: Effect of 0.2 mg daily in subjects with primary hypercholesterolemia.", JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, (1997) 2/1 (7-16). REFS: 30 ISSN: 1074-2484 CODEN: JCPTFE, United States, XP002095846 *

Also Published As

Publication number Publication date
WO1999009967B1 (en) 1999-07-08
CA2300165A1 (en) 1999-03-04
EP1007019A2 (en) 2000-06-14
AU9115398A (en) 1999-03-16
WO1999009967A2 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
WO1999009967A3 (en) Cholesterol-lowering therapy
Eisenberg Cholesterol lowering in the management of coronary artery disease: the clinical implications of recent trials
AU5074196A (en) Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
BR0013704A (en) Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular cases
EP1238667A3 (en) Use of benzothiophenes for treatment of hypercholesterolaemia
PL307463A1 (en) Pharmaceutical agent especially for inhibiting osteoporosis and lowering cholesterol level in blood serum
WO2000028981A3 (en) Methods for treating, preventing, and reducing the risk of the onset of alzheimer's disease using an hmg coa reductase inhibitor
AU5691198A (en) Nonwoven web laminate having relatively hydrophilic zone and related method for its manufacture
WO1999066031A3 (en) Pharmaceutical factor vii preparation
WO2001015676A3 (en) Compositions and methods for modulating hdl cholesterol and triglyceride levels
CA2268439A1 (en) Citrus peel extract as 3-hydroxy-3-methylglutaryl coa(hmg-coa) reductase inhibitor
WO1998051289A3 (en) Monoesters of probucol for the treatment of cardiovascular and inflammatory disease
AU9040098A (en) Compounds and method for the prevention and treatment of diabetic retinopathy
AU2174197A (en) Amphipathic molecules as cholesterol and other lipid uptake inhibitors
EP0713706A3 (en) Lipoprotein (a) lowering agent, cholesterol lowering agent and medicaments comprising these agents respectively
WO2002072104A3 (en) Antihypertensive agent and cholesterol absorption inhibitor combination therapy
EP0989852A4 (en) Method for treating atherosclerosis with an mpt inhibitor and cholesterol lowering drugs
AU2003291206A1 (en) Lactoferrin in the reduction of circulating cholesterol, vascular inflammation, atherosclerosis and cardiovascular disease
WO2000069445A8 (en) Combination therapy for treating hypercholesterolemia
WO2001041754A3 (en) Inhibitors of collagen-induced platelet aggregation
Hunninghake Therapeutic efficacy of the lipid-lowering armamentarium: the clinical benefits of aggressive lipid-lowering therapy
BG105471A (en) Method for preventing or delaying the need for a catheter of the coronary artery
AU5544994A (en) Use of 17alpha-dihydroequilenin for lowering cholesterol
Campeau Lipid lowering and coronary bypass graft surgery
Smith Jr Review of recent clinical trials of lipid lowering in coronary artery disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: B1

Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GE HR HU ID IL IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2300165

Country of ref document: CA

Ref country code: CA

Ref document number: 2300165

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1998943329

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 91153/98

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 1998943329

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1998943329

Country of ref document: EP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载